Replies to post #59703 on Ayala Pharmaceuticals Inc (fka ADXS)

[NY1972]

Highly significant association between neoantigen burden and response to anti-PD-1 therapy (PD + PR vs CR, P = 0.00046). We also observed that, in our cohort, response to anti-PD-1 therapy was more accurately predicted by neoantigen burden than mutational burden.

http://www.abstractsonline.com/pp8/#!/4562/presentation/7990

[jondoeuk]

They are running trials in ndGBM (with Optune), lymphoma (fNHL), NSCLC, breast, renal, prostate, melanoma, bladder, pancreatic and certain hematological malignancies. Here are some PR's from them http://neontherapeutics.com/neon-therapeutics-announces-clinical-trial-collaboration-with-merck/ http://neontherapeutics.com/neon-therapeutics-and-apexigen-announce-immuno-oncology-clinical-trial-collaboration/ http://neontherapeutics.com/vedantra-pharmaceuticals-extends-research-collaboration-with-neon-therapeutics-to-develop-novel-cancer-immunotherapies/